Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Engineered IgA antibody evaluation using blood from healthy volunteers
NL-OMON54864Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of engineered anti-EGFR IgA antibody and engineered anti-EpCAM IgA antibody in cancer and carcinoma, sponsored by Radboud University Medical Center. Primary endpoints: Percent change in tumor cell viability and Percent of cancer cells phagocytosed by macrophages. Started Mar 2022; status: recruiting.
02
Drugs
engineered anti-EGFR IgA antibodyengineered anti-EpCAM IgA antibody
03
Conditions
cancercarcinoma
Beyond the preview
Go deeper on NL-OMON54864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54864.